AstraZeneca’s rare disease unit, Alexion (AZ, NASDAQ: AZN), has signed a significant purchase and license agreement with Pfizer (NYSE: PFE), focusing on a portfolio of preclinical gene therapy programs and related enabling technologies. This strategic deal will provide Alexion with access to several novel adeno-associated virus (capsids), which are crucial for the delivery of gene cargos for gene editing and therapy across a variety of indications. As part of the agreement, a number of Pfizer staff members will transition to Alexion.
Building on an Existing Relationship
The agreement deepens the existing relationship between Alexion and Pfizer, and it comes with a substantial financial commitment. Up to USD 1 billion will be paid through a combination of upfront and milestone payments, demonstrating the significant investment in the potential of these preclinical gene therapy programs. In addition to the upfront and milestone payments, Pfizer will also be entitled to receive a royalty on any future sales of products that emerge from this collaboration.
Expanding Alexion’s Rare Disease Portfolio
This deal is a strategic move for Alexion as it expands its rare disease portfolio and strengthens its position in the gene therapy space. The acquisition of these preclinical programs and technologies will allow Alexion to further explore and develop new treatments for rare diseases, building on its existing expertise in this area.-Fineline Info & Tech
